Abstract
Background and Aims
The effect of the cystic fibrosis transmembrane conductance regulator protein (CFTR) defect in pancreatic insufficient (PI) patients with cystic fibrosis (CF) on the gastrointestinal pH profile is poorly defined. Adequate and efficient neutralization of the gastric acidity in the duodenum is important for nutrient absorption and timely release of pancreatic enzyme replacement therapy (PERT). We utilized a wireless motility capsule (WMC) to study intestinal pH profile and gastrointestinal transit profile in CF subjects.
Methods
WMC studies were done on ten adult CF patients with PI while off acid suppression medication and ten age, gender and BMI matched healthy controls. Mean pH over 1 min increments and area under the pH curve over 5 min increments was calculated for the first hour post gastric emptying. Paired t-test was used to compare means of the pH recordings, transit profiles and analysis of time interval required to reach and maintain pH >5.5 and 6.0.
Results
A statistically significant difference was observed between mean pH values during the first 23 min of small bowel transit (p < 0.05). In CF subjects, there was a significant delay in time interval required to reach and sustain pH 5.5 and pH 6.0 (p < 0.001), which is required for PERT dissolution. Only small bowel transit in CF subjects was noted to be significantly delayed (p = 0.004) without a compensatory increase in whole gut transit time.
Conclusions
We have demonstrated a significant delay in the small intestinal transit and a deficient buffering capacity required to neutralize gastric acid in the proximal small bowel of patients with CF.
Similar content being viewed by others
Abbreviations
- CFTR:
-
Cystic fibrosis transmembrane conductance regulator protein
- CF:
-
Cystic fibrosis
- PERT:
-
Pancreatic enzyme replacement therapy
- WMC:
-
Wireless motility capsule
- PI:
-
Pancreatic insufficiency
- AUC:
-
Area under the curve
- GET:
-
Gastric emptying time
- SBTT:
-
Small bowel transit time
- CTT:
-
Colon transit time
- WGT:
-
Whole gut transit time
- BMI:
-
Body mass index
References
Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27:910–920.
Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol. 1994;34:158–166.
Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009;119:2613–2622.
Chen EY, Yang N, Quinton PM, Chin WC. A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol. 2010;299:L542–L549.
Couper RT, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res. 1992;32:179–182.
Clarke LL, Harline MC. Dual role of CFTR in cAMP-stimulated HCO3- secretion across murine duodenum. Am J Physiol. 1998;274:G718–G726.
Pratha VS, Hogan DL, Martensson BA, Bernard J, Zhou R, Isenberg JI. Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastroenterology. 2000;118:1051–1060.
Dutta SK, Hubbard VS, Appler M. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis. Dig Dis Sci. 1988;33:1237–1244.
Youngberg CA, Berardi RR. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci. 1987;32:472–480.
Borowitz D, Durie PR. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2005;41:273–285.
Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010;45:389–394.
Hasler WL, Coleski R. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1384–G1391.
Rao SSC, Kuo B, McCallum RW, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clinical gastroenterology and hepatology: the official clinical practice. Am J Gastroenterol. 2009;7(5):537–44.
Kuo B, McCallum RW. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27:186–196.
Kaunitz JD, Akiba Y. Review article: duodenal bicarbonate—mucosal protection, luminal chemosensing and acid-base balance. Aliment Pharmacol Ther. 2006;24:169–176.
Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol. 2005;288:C1–C19.
Steward MC, Ishiguro H. Molecular and cellular regulation of pancreatic duct cell function. Curr Opin Gastroenterol. 2009;25:447–453.
Montrose MHA, Yasutada TK, Kaunitz JD. Gastroduodenal mucosal defense. In: Johnson LR, eds. Physiology of the Gastrointestinal Tract. Amsterdam: Elsevier; 2006:1260–1291.
Clarke LL, Stien X, Walker NM. Intestinal bicarbonate secretion in cystic fibrosis mice. JOP. 2001;2:263–267.
Tovar JA, Izquierdo MA, Eizaguirre I. The area under pH curve: a single-figure parameter representative of esophageal acid exposure. J Pediatr Surg. 1991;26:163–167.
Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr. 2003;162:760–763.
Canani RB, Cirillo P. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817–e820.
Ramsey BW, Davies J. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672.
Acknowledgments
The authors would like to thank Gregory E. Wilding for an early discussion on analytical methods of SmartPill data. This study was funded by a grant from Cystic Fibrosis Foundation Therapeutics, Inc. Funding #: BOROWI08A0.
Conflict of interest
Jack Semler is an employee of SmartPill Corporation and owns stock in the corporation. Daniel Gelfond, Changxing Ma and Drucy Borowitz have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was approved by the University of Buffalo Children and Youth Institutional Review Board Children and Youth IRB Women and Children’s Hospital of Buffalo, Buffalo, NY. Approval date: 6 October 2008.
Rights and permissions
About this article
Cite this article
Gelfond, D., Ma, C., Semler, J. et al. Intestinal pH and Gastrointestinal Transit Profiles in Cystic Fibrosis Patients Measured by Wireless Motility Capsule. Dig Dis Sci 58, 2275–2281 (2013). https://doi.org/10.1007/s10620-012-2209-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-012-2209-1